Toxicologic studies of a superpotent alpha-melanotropin, [Nle4, D-Phe7]alpha-MSH. 1988

R T Dorr, and B V Dawson, and F al-Obeidi, and M E Hadley, and N Levine, and V J Hruby
Department of Internal Medicine, University of Arizona, Tucson 85724.

A toxicology study was performed in mice given a superpotent alpha melanocyte stimulating hormone (MSH) analog. This 13 amino acid derivative, [Nle4, D-Phe7]alpha-MSH or NDP-MSH, is a melanotropin which is very slowly biodegraded in vivo and is active at 1/1,000 the concentration of natural alpha-MSH. Mice were administered up to 2 mg/kg of the analog daily and weekly over 4 or 12 weeks by both topical application (in 90% DMSO) or by IP injections (in physiologic saline). At the end of this period, no toxic effects were observed in various organs, on hematologic indices, or on weight gain. A slight increase in triglyceride and platelet levels were noted in mice given the analog weekly for 12 weeks. There was no evidence of an effect on behavior nor ACTH-like endocrine actions such as elevated serum cortisol levels. Transdermal drug delivery studies performed in vitro showed reproducible diffusion of the NDP-MSH analog through full-thickness mouse skin. Approximately 0.002% to 0.05% of a 10(-4) M preparation was transdermally delivered using a DMSO/water solution or a PEG/alcohol cream base, respectively. This superpotent analog is now entering a Phase I clinical trial with possible therapeutic applications for the treatment of hypomelanotic disorders such as vitiligo and for pharmacologic tanning without the need for sunlight exposure.

UI MeSH Term Description Entries
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D008297 Male Males
D008815 Mice, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation. Inbred Mouse Strains,Inbred Strain of Mice,Inbred Strain of Mouse,Inbred Strains of Mice,Mouse, Inbred Strain,Inbred Mouse Strain,Mouse Inbred Strain,Mouse Inbred Strains,Mouse Strain, Inbred,Mouse Strains, Inbred,Strain, Inbred Mouse,Strains, Inbred Mouse
D009152 Mutagenicity Tests Tests of chemical substances and physical agents for mutagenic potential. They include microbial, insect, mammalian cell, and whole animal tests. Genetic Toxicity Tests,Genotoxicity Tests,Mutagen Screening,Tests, Genetic Toxicity,Toxicity Tests, Genetic,Genetic Toxicity Test,Genotoxicity Test,Mutagen Screenings,Mutagenicity Test,Screening, Mutagen,Screenings, Mutagen,Test, Genotoxicity,Tests, Genotoxicity,Toxicity Test, Genetic
D000279 Administration, Cutaneous The application of suitable drug dosage forms to the skin for either local or systemic effects. Cutaneous Drug Administration,Dermal Drug Administration,Drug Administration, Dermal,Percutaneous Administration,Skin Drug Administration,Transcutaneous Administration,Transdermal Administration,Administration, Dermal,Administration, Transcutaneous,Administration, Transdermal,Cutaneous Administration,Cutaneous Administration, Drug,Dermal Administration,Drug Administration, Cutaneous,Skin Administration, Drug,Administration, Cutaneous Drug,Administration, Dermal Drug,Administration, Percutaneous,Administrations, Cutaneous,Administrations, Cutaneous Drug,Administrations, Dermal,Administrations, Dermal Drug,Administrations, Percutaneous,Administrations, Transcutaneous,Administrations, Transdermal,Cutaneous Administrations,Cutaneous Administrations, Drug,Cutaneous Drug Administrations,Dermal Administrations,Dermal Drug Administrations,Drug Administrations, Cutaneous,Drug Administrations, Dermal,Drug Skin Administrations,Percutaneous Administrations,Skin Administrations, Drug,Skin Drug Administrations,Transcutaneous Administrations,Transdermal Administrations
D000521 alpha-MSH A 13-amino acid peptide derived from proteolytic cleavage of ADRENOCORTICOTROPIC HORMONE, the N-terminal segment of ACTH. ACTH (1-13) is amidated at the C-terminal to form ACTH (1-13)NH2 which in turn is acetylated to form alpha-MSH in the secretory granules. Alpha-MSH stimulates the synthesis and distribution of MELANIN in MELANOCYTES in mammals and MELANOPHORES in lower vertebrates. MSH, alpha,alpha Intermedin,alpha-Melanocyte-Stimulating Hormone,(Des-Acetyl)-alpha-MSH,(Desacetyl)alpha-MSH,ACTH (1-13),ACTH (1-13)NH2,ACTH(1-13),Acetylated ACTH (1-13)NH2,Adrenocorticotropin (1-13)NH2,DE-alpha-MSH,Des-Acetyl MSH,Desacetyl alpha-MSH,Desacetyl alpha-Melanocyte-Stimulating Hormone,MSH, (Desacetyl)alpha-,alpha-Melanotropin,Desacetyl alpha MSH,Desacetyl alpha Melanocyte Stimulating Hormone,Hormone, Desacetyl alpha-Melanocyte-Stimulating,Hormone, alpha-Melanocyte-Stimulating,Intermedin, alpha,MSH, Des-Acetyl,alpha MSH,alpha Melanocyte Stimulating Hormone,alpha Melanotropin,alpha-MSH, Desacetyl,alpha-Melanocyte-Stimulating Hormone, Desacetyl
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012486 Salmonella typhimurium A serotype of Salmonella enterica that is a frequent agent of Salmonella gastroenteritis in humans. It also causes PARATYPHOID FEVER. Salmonella typhimurium LT2
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

R T Dorr, and B V Dawson, and F al-Obeidi, and M E Hadley, and N Levine, and V J Hruby
January 1985, Endocrine research,
R T Dorr, and B V Dawson, and F al-Obeidi, and M E Hadley, and N Levine, and V J Hruby
January 1985, Comparative biochemistry and physiology. A, Comparative physiology,
R T Dorr, and B V Dawson, and F al-Obeidi, and M E Hadley, and N Levine, and V J Hruby
October 2000, Photochemistry and photobiology,
R T Dorr, and B V Dawson, and F al-Obeidi, and M E Hadley, and N Levine, and V J Hruby
January 1989, Pigment cell research,
R T Dorr, and B V Dawson, and F al-Obeidi, and M E Hadley, and N Levine, and V J Hruby
March 1984, Life sciences,
R T Dorr, and B V Dawson, and F al-Obeidi, and M E Hadley, and N Levine, and V J Hruby
February 1997, Nuclear medicine and biology,
R T Dorr, and B V Dawson, and F al-Obeidi, and M E Hadley, and N Levine, and V J Hruby
March 1993, Pharmacology, biochemistry, and behavior,
R T Dorr, and B V Dawson, and F al-Obeidi, and M E Hadley, and N Levine, and V J Hruby
June 1988, European journal of pharmacology,
R T Dorr, and B V Dawson, and F al-Obeidi, and M E Hadley, and N Levine, and V J Hruby
May 1993, Annals of the New York Academy of Sciences,
R T Dorr, and B V Dawson, and F al-Obeidi, and M E Hadley, and N Levine, and V J Hruby
April 1988, Neuropeptides,
Copied contents to your clipboard!